Drug Profile

MP 2021

Alternative Names: MP-2021

Latest Information Update: 18 Dec 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator MedPacto
Class Osteoporosis therapies
Mechanism of Action Osteoclast inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Autoimmune disorders; Bone disorders

Most Recent Events

04 Dec 2023 MedPacto plans a phase I trial for Bone disorders in 2024
29 Nov 2023 Pharmacodynamics data from a preclinical trial in autoimmune disorders released by MedPacto
10 Nov 2023 Pharmacodynamics data from a preclinical trial in Autoimmune disorders presented at the ACR Convergence 2023 (ACR-2023)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com